Study of Subcutaneous Campath-1H in Patients With B-Cell CLL and Residual Disease After Chemotherapy

NCT00800943 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

31

Enrollment

NETWORK

Sponsor class

Conditions

B-Cell Chronic Lymphocytic Leukemia

Interventions

BIOLOGICAL: Alemtuzumab (Campath-1H)

Sponsor

Chronic Lymphocytic Leukemia Research Consortium

Collaborators

[object Object]